Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 Folic acid inhibiting drugs Sulfonamides (sulfa drugs) –Early synthetic drugs –Metabolic antagonists, block folic acid biosynthetic pathway –Folic acid.

Similar presentations


Presentation on theme: "1 Folic acid inhibiting drugs Sulfonamides (sulfa drugs) –Early synthetic drugs –Metabolic antagonists, block folic acid biosynthetic pathway –Folic acid."— Presentation transcript:

1 1 Folic acid inhibiting drugs Sulfonamides (sulfa drugs) –Early synthetic drugs –Metabolic antagonists, block folic acid biosynthetic pathway –Folic acid needed for synthesis of nucleotides Selectively toxic: folic acid is a human vitamin –Failure to synthesize DNA bacteriostatic –Resistance common Mutation in enzyme easy Reduced drug uptake also occurs

2 2 trimethoprim Different structure, functions in same pathway –Inhibits different enzyme –Resistance also occurs from changed cell permeability and altered enzyme Used in combinations with sulfonamides –Bactrim: sulfamethoxazole and trimethoprim –Synergistic to the point of being bactericidal –Decreased resistance by mutation from mutation rate being the product of the two rates

3 3 Folic acid inhibiting combos sulfamethoxazole trimethoprim http://en.wikipedia.org/wiki/Trimethoprim

4 4 Pharmacokinetics and use Sulfa drug family generally administered orally –Great variation in disposition, half life –Mostly combos administered Wide variety of pathogens including non-bacterial Treatment of opportunistic infections found with HIV infection Treatment of urinary tract infections Treatment of some chronic respiratory infections

5 5 Side effects of folate inhibitors Hypersensitivities including Stevens-Johnson syndrome –Severe reaction with extensive skin damage and systemic effects Hematological effects including anemias, agranulocytosis, thrombocytopenia

6 6 Polymyxins www.cas.astate.edu/ draganjac/AndreaHausman.html Cyclic peptides of amino acids and amino butyric acid. “R” is a long hydrophobic tail. Source: Bacillus polymyxa Polymyxins interact with OM of Gram negatives, causing leakage of periplasmic enzymes, damage cell membrane.

7 7 Action of Polymyxins

8 8 Polymyxins Can be used iv with caution Toxicity primarily nephro- and neurotoxicity –Expected to have low selective toxicity because of detergent effects on cell membranes. Typically administered topically along with neomycin and bacitracin –Combination covers cell wall inhibition, protein synthesis inhibition, and membrane attack –Effective against Gram positives and negatives

9 9 Fluoroquinolones Based on older drug nalidixic acid Became familiar to public during anthrax scares Inhibit the action of Topoisomerases including Type 2 (includes gyrase) and Topo..ase IV –Bacterial DNA is negatively supercoiled; these enzymes introduce or remove supercoiling and are required for relieving coiling stress during DNA replication. –Inhibition results in cell death due to release of DNA w/ double strand breaks.

10 10 Structure and function Fluoroquinolone nucleus: Type 2 enzymes produce double strand breaks Drug traps DNA- enzyme complex, releases broken DNA.

11 11 Pharmacokinetics and clinical use Fluoroquinolones can all be given orally –Most can also be administered iv Most have fairly long half-life in the body (e.g. >4 hours), good penetration into compartments Mostly renal excretion Active against a wide range of bacteria –Urinary tract and STDs –Tough to kill bacteria –Biowarfare agents (anthrax, plague, tularemia)

12 12 Toxicity Usual wide variety of side effects GI disturbance including C. difficile problems Hypersensitivity with rashes Some degree of neuro- and hepatotixicity Damage to cartilage in developing individuals (i.e. children). Elevated theophylline levels!

13 13 Chapter 49: anti-mycobacterial agents Mycobacterium –M. tuberculosis: cause of tuberculosis Chronic lung disease –M. avium complex (MAC) Environmental opportunist –M. leprae: Hansen’s disease aka leprosy

14 14 Challenges to treatment Chronic diseases, require long term treatment Socio-economic groups –Homeless and poor least likely to continue therapy, breeds resistance Combination therapy required because of developing resistance Bacteria grow intracellularly –Drug must reach target Uncontrolled, contagious infections in immunocompromised

15 15 Selected info on drugs Mixture of synthetic drugs and antibiotics Orally administered as befits long term care –6 to 9 months of treatment Typical drugs: –Isoniazid, ethambutol, rifampicin, pyrazinamide –Include many different modes of action –Some target the unique cell wall consisting of mycolic acids covalently attached to PG

16 16 Antifungal drugs Fungi are eukaryotes, thus removing targets of 70S ribosomes and PG. –Major target: fungal cell membrane –Other drugs target cell wall, nuclear division, and nucleic acid synthesis Except for superficial infections, serious disease rarely occurs in healthy individual –Systemic, serious disease in immunocompromised Older drugs powerful, but more toxic –Amphotericin B, Nystatin, etc.

17 17 Azoles, Allylamines, Tolnaftate Azoles:Fluconazole, ketoconazole, miconazole –Inhibit enzyme in ergosterol pathway, compromising cell membranes –Some oral, some topical, some iv Dependent on absorption properties Terbinafine: allylamine marketed as Lamisil –Concentrated in hair and nails Various azoles, terbinafine, and tolnaftate sold for treatment of superficial infections, OTC

18 18


Download ppt "1 Folic acid inhibiting drugs Sulfonamides (sulfa drugs) –Early synthetic drugs –Metabolic antagonists, block folic acid biosynthetic pathway –Folic acid."

Similar presentations


Ads by Google